Vanda Pharmaceuticals
Quarterly Financials
| Values in thousands | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
Revenue | $57,216 | $56,258 | $52,590 | $50,041 |
Gross Profit | 53,383 | 53,304 | 48,103 | 46,520 |
EBITDA | -34,490 | -29,231 | -32,869 | -31,115 |
EBIT | -40,353 | -31,284 | -34,886 | -32,095 |
Net Income | -141,187 | -22,586 | -27,207 | -29,494 |
Net Change In Cash | 57,216 | 56,258 | 52,590 | 50,041 |
Free Cash Flow | -29,519 | -31,787 | -15,551 | -33,583 |
Cash | 84,851 | 70,022 | 80,983 | 111,796 |
Basic Shares | 59,098 | 58,873 | 58,993 | 58,527 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $216,105 | $198,772 | $192,640 | $254,382 |
Gross Profit | 203,061 | 187,458 | 192,640 | 230,100 |
EBITDA | -139,251 | -32,528 | -13,952 | 9,062 |
EBIT | -151,168 | -40,660 | -13,952 | 6,329 |
Net Income | -220,474 | -18,900 | 2,509 | 6,275 |
Net Change In Cash | 216,105 | 198,772 | 192,640 | 254,382 |
Cost of Revenue | 82,643 | |||
Free Cash Flow | -110,440 | -16,247 | 12,418 | 31,305 |
Cash | 84,851 | 102,316 | 135,821 | 135,029 |
Basic Shares | 58,930 | 58,149 | 57,557 | 56,983 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | $0 |
2025-12-31 | -$2.39 |
2025-09-30 | -$0.38 |
2025-06-30 | -$0.46 |
